Screener
Amneal Pharmaceuticals, Inc. AMRX AvKARE — Gain (Loss) from Litigation Settlement
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossRelatedToLitigationSettlement.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Three Months Ended June 30, 2026 | Affordable Medicines (1) | Specialty | Av KARE | Corporateand Other | Total Company |
|---|---|---|---|---|---|
| Selling, general and administrative | 42,367 | 40,095 | 16,913 | 49,347 | 148,722 |
| Research and development | 33,023 | 5,994 | — | — | 39,017 |
| Intellectual property legal development expenses | 2,002 | 85 | — | — | 2,087 |
| Acquisition costs | — | — | — | 7,600 | 7,600 |
| Restructuring and other charges | — | — | — | 554 | 554 |
| Charges related to legal matters, net | 8,057 | — | — | — | 8,057 |
| Other operating income | (1,298) | — | — | — | (1,298) |
| Operating income (loss) | $123,078 | $54,856 | $9,336 | $(57,501) | $129,769 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s avkare — gain (loss) from litigation settlement?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — gain (loss) from litigation settlement of $0 in Q2 2026.
- What does avkare — gain (loss) from litigation settlement mean?
- Represents the net financial impact of legal settlements recognized within the specific business segment. This metric captures non-recurring gains or losses arising from legal disputes, providing insight into the segment's exposure to litigation risks.
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — gain (loss) from litigation settlement.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude